Dynamic Alterations to Hepatic MicroRNA-29a in Response to Long-Term High-Fat Diet and EtOH Feeding
- PMID: 37834011
- PMCID: PMC10572557
- DOI: 10.3390/ijms241914564
Dynamic Alterations to Hepatic MicroRNA-29a in Response to Long-Term High-Fat Diet and EtOH Feeding
Abstract
MicroRNA-29a (miR-29a) is a well characterized fibro-inflammatory molecule and its aberrant expression is linked to a variety of pathological liver conditions. The long-term effects of a high-fat diet (HFD) in combination with different levels of EtOH consumption on miR-29a expression and liver pathobiology are unknown. Mice at 8 weeks of age were divided into five groups (calorie-matched diet plus water (CMD) as a control group, HFD plus water (HFD) as a liver disease group, HFD plus 2% EtOH (HFD + 2% E), HFD + 10% E, and HFD + 20% E as intervention groups) and fed for 4, 13, 26, or 39 weeks. At each time point, analyses were performed for liver weight/body weight (BW) ratio, AST/ALT ratio, as well as liver histology assessments, which included inflammation, estimated fat deposition, lipid area, and fibrosis. Hepatic miR-29a was measured and correlations with phenotypic traits were determined. Four-week feeding produced no differences between the groups on all collected phenotypic traits or miR-29a expression, while significant effects were observed after 13 weeks, with EtOH concentration-specific induction of miR-29a. A turning point for most of the collected traits was apparent at 26 weeks, and miR-29a was significantly down-regulated with increasing liver injury. Overall, miR-29a up-regulation was associated with a lower liver/BW ratio, fat deposition, inflammation, and fibrosis, suggesting a protective role of miR-29a against liver disease progression. A HFD plus increasing concentrations of EtOH produces progressive adverse effects on the liver, with no evidence of beneficial effects of low-dose EtOH consumption. Moreover, miR-29a up-regulation is associated with less severe liver injury.
Keywords: EtOH; high-fat diet; liver; long-term feeding; microRNA.
Conflict of interest statement
There are none for this paper. For full disclosure, Chalasani has ongoing paid consulting activities (or had in the preceding 12 months) with Madrigal, Altimmune, GSK, Pfizer, Merck, Ventyx, Foresite labs, Galectin, and Zydus. These consulting activities are generally in the areas of nonalcoholic fatty liver disease and drug hepatotoxicity. Chalasani receives research grant support from DSM and Exact Sciences, where his institution receives the funding. He is an equity owner in Avant Sante Therapeutics, LLC, a contract research organization. Zimmers is on the scientific advisory board for Emmyon, Inc. and PeleOs, LLC. Gawrieh consults for TransMedics and Pfizer, and receives grant support from Cirius, Viking, and Zydus. Liang, Saxena, and Zhong, and Williams have nothing to disclose for this research.
Figures









References
-
- Jarvis H., Craig D., Barker R., Spiers G., Stow D., Anstee Q.M., Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17:e1003100. doi: 10.1371/journal.pmed.1003100. - DOI - PMC - PubMed